335. Measles, Mumps, and Rubella Serostatus among an HIV-infected cohort and response to MMR vaccination
Session: Poster Abstract Session: HIV Co-morbidities
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
  • mmr poster 42x84 9 26 13 draft.pdf (334.0 kB)
  • Background:

    M/M/R (measles, mumps, and rubella) are preventable illnesses that are often more severe among HIV-infected individuals. Outbreaks of these Illnesses continue to occur.  Frequency of M/M/R seronegativity among HIV-infected patients is not well studied and there are no guidelines for assessing M/M/R status among HIV-infected patients.


    We performed a retrospective chart review of adult HIV-infected patients in a NYC HIV clinic from 1998-2011 who had any M/M/R serology assessment to characterize factors associated with seropositivity. In addition, we reviewed MMR vaccination records, longitudinal HIV variables at 3, 6, and 12 months, and any follow-up M/M/R serology assessment. We used univariate and multivariate logistic regression to determine factors associated with M/M/R seropositivity individually.


    1481 HIV-infected patients had measles, mumps, or rubella serology assessed. Of the cohort, 32% were female, median age 42.8 years, and mean duration of HIV infections 9.9 years. The median CD4 was 431 cells/mm3, and 44% had plasma HIV-1 RNA<400 copies/mL. Seropositivity for M/M/R were 85.3%, 85.6%, and 87.2%, respectively.  In multivariate analysis, measles seropositivity was associated with older age (OR 1.08 per year, p<0.001) and shorter duration of HIV (OR 0.93 per year, p<0.001); mumps seropositivity was associated with older age (OR 1.04 per year, p<0.001) and shorter duration of HIV (OR 0.94 per year, p<0.001); and rubella seropositivity was associated with older age (OR 1.04 per year, p<0.001), shorter duration of HIV (OR 0.94 per year, p<0.001), and female gender (OR 1.86, p<0.001). Among our cohort of 1481 individuals, 163 received vaccination. There were no significant changes at CD4 and viral through 12 months post-vaccination. There were 28, 13, and 16 M/M/R non-immune patients who had post-vaccination results at a median duration of 17-24 months. Of these 57%, 54%, and 81% seroconverted.


    We found approximately 15% M/M/R seronegativity among a large, diverse cohort of HIV-infected individuals; especially among younger patients and with longer duration of HIV. MMR immunization was followed by reasonable seroconversion without impact on HIV control. Further studies should better characterize vaccine responses.

    Harjot Singh, MD/ScM, Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, Ya-Lin Chiu, Weill Cornell Medical College, new york city, NY and Timothy Wilkin, MD/MPH, Weill Medical College of Cornell University, New York, NY


    H. Singh, None

    Y. L. Chiu, None

    T. Wilkin, Weill Cornell: Ad hoc consultant to Merck and Consultant, Research grant and Research grants paid to Weill Cornell from GlaxoSmithKline/ViiV, Janssen, and Gilead

    See more of: HIV Co-morbidities
    See more of: Poster Abstract Session
    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.